Abstract
Infliximab, a novel chimeric anti-tumor necrosis factor-α (TNF-α) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing regimen is lacking in the published literature. A variety of dosing regimens have been suggested, including a treatment schedule similar to that of psoriasis. The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.
Original language | English (US) |
---|---|
Pages (from-to) | 702-704 |
Number of pages | 3 |
Journal | Journal of Drugs in Dermatology |
Volume | 9 |
Issue number | 6 |
State | Published - Jun 1 2010 |
ASJC Scopus subject areas
- Dermatology